Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer... ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Mehr anzeigen
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost...
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing...
Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE...
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with heavily pretreated HER2-positive breast...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -6.11111111111 | 1.8 | 1.865 | 1.56 | 634973 | 1.6857719 | CS |
| 4 | 0.16 | 10.4575163399 | 1.53 | 1.965 | 1.51 | 866097 | 1.72731762 | CS |
| 12 | 0.19 | 12.6666666667 | 1.5 | 2.05 | 1.21 | 1008682 | 1.56785922 | CS |
| 26 | -6.3737 | -79.0418790382 | 8.0637 | 8.11 | 1.21 | 1039602 | 2.43417525 | CS |
| 52 | -12.11 | -87.7536231884 | 13.8 | 17.825 | 1.21 | 840925 | 5.76524364 | CS |
| 156 | -16.36 | -90.6371191136 | 18.05 | 20.4 | 1.21 | 570557 | 7.71669518 | CS |
| 260 | -28.75 | -94.4480946124 | 30.44 | 117.45 | 1.21 | 463564 | 16.32760195 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
